Skip to main content

Lanadelumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jul 19, 2023.

Applies to lanadelumab: subcutaneous solution.

Serious side effects of Lanadelumab

Along with its needed effects, lanadelumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lanadelumab:

More common

Less common

Other side effects of Lanadelumab

Some side effects of lanadelumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to lanadelumab: subcutaneous solution.

General

The most common adverse reactions were injection site reactions, upper respiratory infection, headache, rash, myalgia, dizziness, and diarrhea.[Ref]

Respiratory

Very common (10% or more): Upper respiratory infection (up to 44%)

Frequency not reported: Viral upper respiratory infection[Ref]

Nervous system

Very common (10% or more): Headache (up to 33%), dizziness (up to 10%)

Frequency not reported: Tension headache, sinus headache[Ref]

Immunologic

Very common (10% or more): Anti-drug antibody (ADA)-positive sample during treatment with this drug (12%)

Common (1% to 10%): Hypersensitivity[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (up to 11%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 11%)[Ref]

Hepatic

Common (1% to 10%): ALT increased, AST increased, ALT or AST greater than 8 times the upper limit of normal[Ref]

Local

Very common (10% or more): Injection site reactions (up to 56%)

Frequency not reported: Pain, erythema, bruising, hematoma, hemorrhage, pruritus, swelling, induration, paresthesia, warmth, edema, rash[Ref]

Dermatologic

Very common (10% or more): Rash (up to 10%)

Frequency not reported: Maculopapular rash, erythematous rash[Ref]

Frequently asked questions

References

1. Product Information. Takhzyro (lanadelumab). Dyax Corporation. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.